Apixaban associated with lower risk of GI bleeding compared to all DOACs
A multinational cohort study of persons with atrial fibrillation (AF) found that compared with all direct oral anticoagulants (DOACs), apixaban was associated with lower rates of gastrointestinal (GI) bleeding but similar rates of ischemic stroke, intracranial hemorrhage (ICH), and all-cause mortality. The findings are published in Annals of Internal Medicine.
DOACs are commonly used to prevent strokes in persons with AF. However, there is not clear guidance for choosing among the four available DOACs because head-to head clinical trial data are not available.
Researchers from University College London studied more than 500,000 new DOAC users in France, Germany, the United Kingdom, and the United States to compare outcomes and adverse effects. They analyzed data for 281,320 apixaban users; 61,008 dabigatran users; 12,722 edoxaban users; and 172,176 rivaroxaban users. They found that use of apixaban was associated with lower rates of GI bleeding compared to other DOACs.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.